Boothbay Fund Management LLC Acquires New Shares in Zura Bio Limited $ZURA

Boothbay Fund Management LLC acquired a new position in shares of Zura Bio Limited (NASDAQ:ZURA) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 824,078 shares of the company’s stock, valued at approximately $3,568,000. Boothbay Fund Management LLC owned approximately 1.27% of Zura Bio as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. JPMorgan Chase & Co. lifted its holdings in shares of Zura Bio by 78.7% in the second quarter. JPMorgan Chase & Co. now owns 4,659,951 shares of the company’s stock worth $4,893,000 after buying an additional 2,052,732 shares in the last quarter. Suvretta Capital Management LLC increased its holdings in Zura Bio by 12.6% during the 3rd quarter. Suvretta Capital Management LLC now owns 5,472,891 shares of the company’s stock worth $23,698,000 after acquiring an additional 611,952 shares during the period. Ameriprise Financial Inc. purchased a new stake in Zura Bio in the 3rd quarter worth approximately $2,165,000. Atika Capital Management LLC purchased a new stake in Zura Bio in the 3rd quarter worth approximately $1,195,000. Finally, UBS Group AG boosted its holdings in Zura Bio by 878.3% in the 3rd quarter. UBS Group AG now owns 305,329 shares of the company’s stock valued at $1,322,000 after purchasing an additional 274,118 shares during the period. Hedge funds and other institutional investors own 61.14% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. Wedbush started coverage on shares of Zura Bio in a report on Monday, February 9th. They issued an “outperform” rating and a $15.00 price target on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Zura Bio in a research note on Friday, January 9th. Finally, Leerink Partners upgraded Zura Bio to a “strong-buy” rating in a research note on Sunday, November 23rd. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $11.60.

Insider Transactions at Zura Bio

In other news, major shareholder Ai Biotechnology Llc acquired 2,000,000 shares of the business’s stock in a transaction dated Thursday, February 26th. The stock was purchased at an average cost of $6.25 per share, for a total transaction of $12,500,000.00. Following the acquisition, the insider owned 6,552,725 shares of the company’s stock, valued at $40,954,531.25. This trade represents a 43.93% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 22.10% of the stock is currently owned by company insiders.

Zura Bio Stock Performance

NASDAQ ZURA opened at $6.28 on Tuesday. Zura Bio Limited has a 52-week low of $0.97 and a 52-week high of $7.44. The company has a fifty day moving average of $6.10 and a 200-day moving average of $4.45. The company has a market capitalization of $408.33 million, a P/E ratio of -9.66 and a beta of 0.18.

Zura Bio Profile

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.